Development of Liposomal Formulations of Zinc Diethyldithiocarbamate for Colorectal Cancer Treatment

Abstract

(DDC)2Zn, disulfiram (DS) metabolite, has shown promising anticancer effects in vitro but further investigations in vivo are limited by its poor water solubility. In this study, liposomes are assessed as a delivery system for (DDC)2Zn. Liposomes were prepared by the thin-film hydration method, followed by high-pressure homogenisation (HPH) for size reduction. The nano-liposomes were then characterised by size, polydispersity index (PDI), zeta potential (ZP), drug loading and encapsulation efficiencies(DLE% and EE%), and MTT cytotoxicity assay. The HSPC-based (PBS) liposomes showed a nano-range of sizes (< 200nm), good PDI (<0.5) but moderate EE%(<40%). However, (DDC)2Zn liposomal formulations showed enhanced cytotoxic activities toward colorectal cancer cells. Therefore, liposomal formulations of(DDC)2Zn with improved DLE% and EE% might have immense potential in cancer therapy.

Keywords

Disulfiram, Zinc, Colorectal cancer, Liposomes, diethyldithiocarbamate

How to Cite

Ansari-Fard, N., Kaya, A., Alves, D., Arafat, B., Pierscionek, B. & Najlah, M., (2022) “Development of Liposomal Formulations of Zinc Diethyldithiocarbamate for Colorectal Cancer Treatment”, British Journal of Pharmacy 7(2). doi: https://doi.org/10.5920/bjpharm.1148

409

Views

91

Downloads

Share

Authors

Niusha Ansari-Fard (Anglia Ruskin University)
Ayse Kaya (Anglia Ruskin University)
Dan Alves (Anglia Ruskin University)
Basel Arafat (Anglia Ruskin University)
Barbara Pierscionek (Anglia Ruskin University)
Mohammad Najlah (Anglia Ruskin University)

Download

Issue

Dates

Licence

Creative Commons Attribution 4.0

Identifiers

File Checksums (MD5)

  • Full text: 2bdaf0e0f909cf94eb697762fb3ba9ef